These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11254460)

  • 1. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.
    Hruz PW; Murata H; Mueckler M
    Am J Physiol Endocrinol Metab; 2001 Apr; 280(4):E549-53. PubMed ID: 11254460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy.
    Murata H; Hruz PW; Mueckler M
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):1-8. PubMed ID: 12462148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.
    Churchill DR; Pym AS; Babiker AG; Back DJ; Weber JN
    Br J Clin Pharmacol; 1998 Nov; 46(5):518-9. PubMed ID: 9833608
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
    Gonzalez-Tome MI; Amador JT; Peña MJ; Gomez ML; Conejo PR; Fontelos PM
    BMC Infect Dis; 2008 Oct; 8():144. PubMed ID: 18945352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy.
    Chaparro J; Reeds DN; Wen W; Xueping E; Klein S; Semenkovich CF; Bae KT; Quirk EK; Powderly WG; Yarasheski KE; Li E
    Metabolism; 2005 May; 54(5):561-7. PubMed ID: 15877283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients].
    Knobel H; Goday A; Grau S
    Med Clin (Barc); 1998 Nov; 111(15):599. PubMed ID: 9859098
    [No Abstract]   [Full Text] [Related]  

  • 8. Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens.
    Moyle G
    AIDS Patient Care STDS; 2002 Dec; 16(12):585-97. PubMed ID: 12542932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.
    Estrada V; De Villar NG; Larrad MT; López AG; Fernández C; Serrano-Rios M
    Clin Infect Dis; 2002 Jul; 35(1):69-76. PubMed ID: 12060877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral drug treatment for HIV/AIDS.
    Goldschmidt RH; Moy A
    Am Fam Physician; 1996 Aug; 54(2):574-80, 587-8. PubMed ID: 8701838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
    Xu A; Yin S; Wong L; Chan KW; Lam KS
    Endocrinology; 2004 Feb; 145(2):487-94. PubMed ID: 14592951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences.
    Mathé G
    Biomed Pharmacother; 1999 Dec; 53(10):449-51. PubMed ID: 10665336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
    Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
    Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.
    Bastard JP; Caron M; Vidal H; Jan V; Auclair M; Vigouroux C; Luboinski J; Laville M; Maachi M; Girard PM; Rozenbaum W; Levan P; Capeau J
    Lancet; 2002 Mar; 359(9311):1026-31. PubMed ID: 11937183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia.
    Yarasheski KE; Tebas P; Claxton S; Marin D; Coleman T; Powderly WG; Semenkovich CF
    Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E899-905. PubMed ID: 12837664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
    Waring JF; Ciurlionis R; Marsh K; Klein LL; Degoey DA; Randolph JT; Spear B; Kempf DJ
    Arch Toxicol; 2010 Apr; 84(4):263-70. PubMed ID: 20213465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
    Maher B; Lloyd J; Wilkins EG; Fraser WD; Back D; Park BK; Pirmohamed M
    Antivir Ther; 2004 Dec; 9(6):879-87. PubMed ID: 15651746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus.
    Carper MJ; Cade WT; Cam M; Zhang S; Shalev A; Yarasheski KE; Ramanadham S
    Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E558-67. PubMed ID: 18171911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.